



Leveraging Global Pediatric Drug Development

Our 2-day virtual symposium in 2021 brought together thought leaders and innovators to share and collaborate on ideas to advance pediatric drug development into a new era.

1,500+
Views

400+
Registrants



Children are not small adults - Why¹?



Diversity in metabolism




Diversity in side effects



Diversity in formulations

Most prescribed treatments for children are not adequately tested in children, resulting in more harm than benefit.²



New Horizon's priority is to overcome these challenges by sharing ways to transform and accelerate pediatric drug development opportunities.

Multifaceted Approach To Pediatric Drug Development



Challenges & opportunities



Utilization of real world data & evidence



Patient engagement & network collaborations

Regulatory framework, policies and collaborations



Novel clinical trial designs - Research methodologies



Modeling & simulation - Tools & extrapolation strategies



Children-specific drugs can be feasible through increased global collaboration, improved applications, innovative designs, and the involvement of families.

References

1. Klassen TP, et al. PLoS medicine. 2008 Aug;5(8):e172.
2. Khan-Bolukiand HundtF. GMS German Medical Science. 2008;6.